Microarrays as validation strategies in clinical samples: Tissue and protein microarrays

OMICS A Journal of Integrative Biology

Volumn 10, Issue 3, 2006, Pages 311-326

  Aguilar Mahecha, Adriana ^a   Hassan, Saima ^a   Ferrario, Cristiano ^a   Basik, Mark ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; PARAFFIN;

BIOPSY; BLOOD SAMPLING; CARCINOMA IN SITU; CELL LYSATE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY; LASER CAPTURE MICRODISSECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; TISSUE MICROARRAY; VALIDATION PROCESS;

ANIMALS; BLOOD CHEMICAL ANALYSIS; HUMANS; PROTEIN ARRAY ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 33750937356     PISSN: 15362310     EISSN: None     Source Type: Journal    
DOI: 10.1089/omi.2006.10.311     Document Type: Review

References (111)

1. AGUILAR-MAHECHA, A., CANTIN, C., DENEAULT, J.S., et al. (2006). Development of reverse-phase protein arrays for the validation of newly discovered biomarkers in plasma or serum. Presented at the Second Annual Conference of US HUPO, Boston.
2. AL-KURAYA, K., SCHRAML, P., TORHORST, J., et al. (2004). Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64, 8534-8540.
3. ALKUSHI, A., IRVING, J., HSU, F., et al. (2003). Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 442, 271-277.
4. ANDERSON, N.L., and ANDERSON, N.G. (2002). The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1, 845-867.
5. ASHIDA, S., FURIHATA, M., KATAGIRI, T., et al. (2006). Expression of novel molecules, MICAL2-PV (MICAL2 prostate cancer variants), increases with high Gleason score and prostate cancer progression. Clin Cancer Res 12, 2767-2773.
6. BAUER, K.D., DE LA TORRE-BUENO, J., DIEL, I.J., et al. (2000). Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res 6, 3552-3559.
7. BELLUCO, C., MAMMANO, E., PETRICOIN, E., et al. (2005). Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. Clin Chim Acta 357, 180-183.
8. BERGER, A.J., CAMP, R.L., DIVITO, K.A., et al. (2004). Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res 64, 8767-8772.
9. BERGER, A.J., DAVIS, D.W., TELLEZ, C., et al. (2005). Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res 65, 11185-11192.
10. BERTHEAU, P., CAZALS-HATEM, D., MEIGNIN, V., et al. (1998). Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 51, 370-374.
11. BHARGAVA, R., OPPENHEIMER, O., GERALD, W., et al. (2005). Identification of MYCN gene amplification in neuroblastoma using chromogenic in situ hybridization (QSH): an alternative and practical method. Diagn Mol Pathol 14, 72-76.
12. BRAND, J., HASLBERGER, T., ZOLG, W., et al. (2006). Depletion efficiency and recovery of trace markers from a multiparameter immunodepletion column. Proteomics 6, 3236-3242.
13. BUBENDORF, L., KONONEN, J., KOIVISTO, P., et al. (1999). Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59, 803-806.
14. CALLAGY, G., PHAROAH, P., CHIN, S.F., et al. (2005). Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 205, 388-396.
15. CALVERT, V.S., TANG, Y., BOVEIA, V., et al. (2004). Development of multiplexed protein profiling and detection using near infrared detection of reverse phase protein microarrays. Clinical Proteomics Journal 1, 81-89.
16. CAMP, R.L., CHARETTE, L.A., and RIMM, D.L. (2000). Validation of tissue microarray technology in breast carcinoma. Lab Invest 80, 1943-1949.
17. CAMP, R.L., CHUNG, G.G., and RIMM, D.L. (2002). Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8, 1323-1327.
18. CAMP, R. L., DOLLED-FILHART, M., KING, B. L., et al. (2003). Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 63, 1445-1448.
19. CHAN, S. M., ERMANN, J., SU, L., et al. (2004). Protein microarrays for multiplex analysis of signal transduction pathways. Nat Med 10, 1390-1396.
20. CHEN, G., GHARIB, T.G., HUANG, C.C., et al. (2002). Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 1, 304-13.
21. CHARBONEAU, L., SCOTT, H., CHEN, T., et al. (2002). Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic 1, 305-315.
22. CHUNG, G.G., YOON, H.H., ZERKOWSKI, M.P., et al. (2006). Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 106, 1677-1684.
23. CORZO, C., COROMINAS, J.M., TUSQUETS, I., et al. (2006). The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. Cancer Genet Cytogenet 165, 151-156.
24. COWHERD, S.M., ESPINA, V.A., PETRICOIN, E.F., 3RD et al. (2004). Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein microarrays. Clin Breast Cancer 5, 385-392.
25. COX, M.L., SCHRAY, C.L., LUSTER, C.N., et al. (2006) Assessment of fixatives, fixation, and tissue processing on morphology and RNA integrity. Exp Mol Pathol. 80, 183-191.
26. CRETICH, M., DAMIN, F., PIRRI, G., et al. (2006). Protein and peptide arrays: recent trends and new directions. Biomol Eng 23, 77-88.
27. DESCAZEAUD, A., DE LA TAILLE, A., ALLORY, Y., et al. (2006). Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system. Prostate 66, 1037-1043.
28. DIVITO, K.A., BERGER, A.J., CAMP, R.L., et al. (2004a). Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res 64, 8773-8777.
29. DIVITO, K.A., CHARETTE, L.A., RIMM, D.L. et al. (2004b). Long-term preservation of antigenicity on tissue microarrays. Lab Invest 84, 1071-1078.
30. ECHAN, L.A., TANG, H.Y., ALI-KHAN, N., et al. (2005). Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics 5, 3292-3303.
31. ESPINA, V., MEHTA, A.I., WINTERS, M.E., et al. (2003). Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 3, 2091-2100.
32. ESPINA, V., WOODHOUSE, E.C., WULFKUHLE, J., et al. (2004). Protein microarray detection strategies: focus on direct detection technologies. J Immunol Methods 290, 121-133.
33. FEJZO, M.S. and SLAMON, D.J. (2001). Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am J Pathol 159, 1645-1650.
34. FERGENBAUM, J.H., GARCIA-CLOSAS, M., HEWITT, S.M., et al. (2004). Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev 13, 667-672.
35. FERNEBRO, E., DICTOR, M., BENDAHL, P.O., et al. (2002). Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med 126, 702-705.
36. FREIER, K., JOOS, S., FLECHTENMACHER, C., et al. (2003). Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 63, 1179-1182.
37. GANCBERG, D., DI LEO, A., ROUAS, G., et al. (2002). Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. J Clin Pathol 55, 315-317.
38. GARCIA, J.F., CAMACHO, F.I., MORENTE, M., et al. (2003). Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 101, 681-689.
39. GEHO, D., LAHAR, N., GURNANI, P., et al. (2005). Pegylated, steptavidin-conjugated quantum dots are effective detection elements for reverse-phase protein microarrays. Bioconjug Chem 16, 559-566.
40. GILTNANE, J.M. and RIMM, D.L. (2004). Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol 1, 104-111.
41. GOMAA, W., KE, Y., FUJII, H. et al. (2005). Tissue microarray of head and neck squamous carcinoma: validation of the methodology for the study of cutaneous fatty acid-binding protein, vascular endothelial growth factor, involucrin and Ki-67. Virchows Arch 447, 701-709.
42. GRUBB, R.L., CALVERT, V.S., WULKUHLE, J.D., et al. (2003). Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 3, 2142-2146.
43. GULMANN, C., ESPINA, V., PETRICOIN, E., 3RD, et al. (2005). Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res 11, 5847-5855.
44. GULMANN, C., SHEEHAN, K.M., KAY, E.W., et al. (2006). Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics and therapy guidance in cancer. J Pathol 208, 595-606.
45. GYGI, S.P., ROCHON, Y., FRANZA, B.R., et al. (1999). Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19, 1720-1730.
46. HARIGOPAL, M., BERGER, A.J., CAMP, R.L., et al. (2005). Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Clin Cancer Res 11, 4083-4089.
47. HEDVAT, C.V., HEGDE, A., CHAGANTI, R.S., et al. (2002). Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 33, 968-974.
48. HENDRIKS, Y., FRANKEN, P., DIERSSEN, J.W., et al. (2003). Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol 162, 469-477.
49. HILBE, W., GACHTER, A., DUBA, H.C., et al. (2003). Comparison of automated cellular imaging system and manual microscopy for immunohistochemically stained cryostat sections of lung cancer specimens applying p53, ki-67 and p120. Oncol Rep 10, 15-20.
50. HUANG, L., HARVIE, G., FEITELSON, J.S., et al. (2005). Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. Proteomics 5, 3314-3328.
51. HULMES, J.D., BETHEA, D., HO, K., et al. (2004). An investigation of plasma collection, stabilization, and storage procedures for proteomic analysis of clinical samples. Journal of Clinical Proteomics 1, 17-31.
52. JACOBS, T.W., PRIOLEAU, J.E., STILLMAN, I.E., et al. (1996). Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 88, 1054-1059.
53. JANZI, M., ODLING, J., PAN-HAMMARSTROM, Q., et al. (2005). Serum microarrays for large scale screening of protein levels. Mol Cell Proteomics 4, 1942-1947.
54. JAYANTHI, S., DENG, X., LADENHEIM, B., et al. (2005) Calcineurin/NFAT- induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis. Proc Natl Acad Sci U S A 102, 868-873.
55. JIANG, Z. and WODA, B.A. (2004). Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy. Adv Anat Pathol 11, 316-321.
56. JIANG, Z., WU, C.L., WODA, B.A., et al. (2004). Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathology 45, 218-225.
57. KERSTING, C., PACKEISEN, J., LEIDINGER, B., et al. (2006), Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J Clin Pathol 59, 585-590.
58. KONONEN, J., BUBENDORF, L., KALLIONIEMI, A., et al. (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4, 844-847.
59. KORABIOWSKA, M., BAUER, H., QUENTIN, T., et al. (2004). Application of new in situ hybridization probes for Ku70 and Ku80 in tissue microarrays of paraffin-embedded malignant melanomas: correlation with immunohistochemical analysis. Hum Pathol 35, 210-216.
60. KORSCHING, E., PACKEISEN, J., AGELOPOULOS, K., et al. (2002). Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82, 1525-1533.
61. KRIEG, R.C., KNUECHEL, R., SCHIFFMANN, E., et al. (2004). Mitochondrial proteome: cancer-altered metabolism associated with cytochrome c oxidase subunit level variation. Proteomics 4, 2789-2795.
62. LIOTTA, L.A., ESPINA, V., MEHTA, A.I., et al. (2003). Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3, 317-325.
63. LIU, Y.J., YAN, P. S., LI, J., et al. (2005). Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. World J Gastroenterol 11, 6601-6606.
64. LUO, J., ZHA, S., GAGE, W.R., et al. (2002). Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62, 2220-2226.
65. MAKRETSOV, N.A., HUNTSMAN, D.G., NIELSEN, T. O., et al. (2004). Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 10, 6143-6151.
66. MENDRZYK, F., KORSHUNOV, A., BENNER, A., et al. (2006). Identification of gains on Iq and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 12, 2070-2079.
67. MERSEBURGER, A.S., KUCZYK, M.A., SERTH, J., et al. (2003). Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol Rep 10, 223-228.
68. MIRCEAN, C., SHMULEVICH, I., COGDELL, D., et al. (2005). Robust estimation of protein expression ratios with lysate microarray technology. Bioinformatics 21, 1935-1942.
69. MIRLACHER, M., KASPER, M., STORZ, M., et al. (2004). Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol 17, 1414-1420.
70. NILSSON, P., PAAVILAINEN, L., LARSSON, K., et al. (2005). Towards a human proteome atlas: high-throughput generation of mono-specific antibodies for tissue profiling. Proteomics 5, 4327-4337.
71. NISHIZUKA, S., CHARBONEAU, L., YOUNG, L., et al. (2003a). Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 100, 14229-14234.
72. NISHIZUKA, S., CHEN, S.T., GWADRY, F.G., et al. (2003b). Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 63, 5243-5250.
73. NOCITO, A., BUBENDORF, L., TINNER, E.M., et al. (2001). Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 194, 349-357.
74. O'GRADY, A., FLAHAVAN, C.M., KAY, E.W., et al. (2003). HER-2 analysis in tissue microarrays of archival human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol 11, 177-182.
75. OLLE, E.W., MESSAMORE, J., DEOGRACIAS, M.P., et al. (2005). Comparison of antibody array substrates and the use of glycerol to normalize spot morphology. Exp Mol Pathol 79, 206-209.
76. PACIFICO, M.D., GROVER, R., RICHMAN, P., et al. (2004). Validation of tissue microarray for the immunohistochemical profiling of melanoma. Melanoma Res 14, 39-42.
77. PALLARES, J., MARTINEZ-GUITARTE, J.L., DOLCET, X., et al. (2005). Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3. Int J Gynecol Pathol 24, 247-253.
78. PARK, K., KIM, J., LIM, S., et al. (2003). Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol 16, 937-947.
79. PAWELETZ, C.P., CHARBONEAU, L., BICHSEL, V.E., et al. (2001). Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981-1989.
80. PSYRRI, A., KASSAR, M., YU, Z., et al. (2005a). Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 11, 8637-8643.
81. PSYRRI, A., YU, Z., WEINBERGER, P.M., et al. (2005b). Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 11, 5856-5862.
82. QIU, J., MADOZ-GURPIDE, J., MISEK, D.E., et al. (2004). Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 3, 261-267.
83. RAI, A.J., GELFAND, C.A., HAYWOOD, B.C., et al. (2005). HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 5, 3262-3277.
84. RAMASWAMY, A., LIN, E., CHEN, I., et al. (2005). Application of protein lysate microarrays to molecular marker verification and quantification. Proteome Sci 3, 9.
85. ROSEN, D.G., HUANG, X., DEAVERS, M.T., et al. (2004). Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 17, 790-797.
86. RUBIN, M.A., ZERKOWSKI, M.P., CAMP, R.L., et al. (2004). Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol 164, 831-840.
87. RUBIN, M.A., ZHOU, M., DHANASEKARAN, S.M., et al. (2002). Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. Jama 287, 1662-1670.
88. SALVUCCI, O., BOUCHARD, A., BACCARELLI, A., et al. (2006). The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 97, 275-283.
89. SELIGSON, D.B., PANTUCK, A.J., LIU, X., et al. (2004). Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 10, 2659-2669.
90. SHEEHAN, K.M., CALVERT, V.S., KAY, E.W., et al. (2005). Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4, 346-355.
91. SHIA, J., KLIMSTRA, D.S., LI, A.R., et al. (2005). Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol 18, 1350-1356.
92. SIMON, R., MIRLACHER, M., and SAUTER, G. (2005). Tissue microarrays. Methods Mol Med 114, 257-268.
93. SRIVASTAVA, M., EIDELMAN, O., JOZWIK, C., et al. (2006). Serum proteomic signature for cystic fibrosis using an antibody microarray platform. Mol Genet Metab 87, 303-310.
94. TOLGAY OCAL, I., DOLLED-FILHART, M., D'AQUILA, T.G., et al. (2003). Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 97, 1841-1848.
95. TORHORST, J., BUCHER, C., KONONEN, J., et al. (2001). Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159, 2249-2256.
96. UHLEN, M., BJORLING, E., AGATON, C., et al. (2005). A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 4, 1920-1932.
97. UHLEN, M. and PONTEN, F. (2005). Antibody-based proteomics for human tissue profiling. Mol Cell Proteomics 4, 384-393.
98. WANG, S., SABOORIAN, M.H., FRENKEL, E.P., et al. (2001). Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 116, 495-503.
99. WATANABE, A., CORNELISON, R., and HOSTETTER, G. (2005). Tissue microarrays: applications in genomic research. Expert Rev Mol Diagn 5, 171-181.
100. WEI, Q., WANG, L.E., STURGIS, E.M., et al. (2005). Expression of nucleotide excision repair proteins in lymphocytes as a marker of susceptibility to squamous cell carcinomas of the head and neck. Cancer Epidemiol Biomarkers Prev 14, 1961-1966.
101. WU, C.L., YANG, X.J., TRETIAKOVA, M., et al. (2004). Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 35, 1008-1013.
102. WULFKUHLE, J.D., AQUINO, J. A., CALVERT, V.S., et al. (2003). Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3, 2085-2090.
103. WULFKUHLE, J.D., EDMISTON, K.H., LIOTTA, L.A., et al. (2006). Technology Insight: pharmacoproteomics for cancer-promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol 3, 256-268.
104. XIE, D., SHAM, J.S., ZENG, W.F., et al. (2003). Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 107, 896-902.
105. XING, X., LAI, M., WANG, Y., et al, (2006) Overexpression of glucose-regulated protein 78 in colon cancer. Clin Chim Acta 364, 308-315.
106. YANG, X., CHARETTE, L.A., GARCIA-CLOSAS, M., et al. (2006) Construction and validation of tissue microarrays of non-invasive structures associated with invasive breast carcinoma. AACR 97th annual meeting, Washington, DC.
107. YU, Z., WEINBERGER, P.M., HAFFTY, B.G., et al. (2005). Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin Cancer Res 11, 1160-1166.
108. ZAHARIEVA, B., SIMON, R., RUIZ, C., et al. (2005). High-throughput tissue microarray analysis of C-MYC amplification urinary bladder cancer. Int J Cancer 20, 952-956.
109. ZHANG, D., SALTO-TELLEZ, M., DO, E., et al. (2003). Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 34, 362-368.
110. ZHANG, H., CHENG, X., RICHTER, M., et al. (2006). A sensitive and high-throughput assay to detect low-abundance proteins in serum. Nat Med 12, 473-477.
111. ZHENG, M., SIMON, R., MIRLACHER, M., et al. (2004). TRIO amplification and abundant mRNA expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Am J Pathol 165, 63-69.